Allergic reactions (acute, severe forms), hemotransfusion shock, anaphylactic shock, anaphylactoid reactions.
Swelling of the brain (including in the background of a brain tumour or associated with surgery, radiation therapy or head trauma).
Bronchial asthma (severe form), asthmatic status.
Systemic diseases of connective tissue (ACS, rheumatoid arthritis).
Acute adrenal insufficiency.
Acute hepatitis, hepatic coma.
Poisoning with caustic fluids (reducing inflammation and preventing scar contraction).
Prolix Hypersensitivity is the only contraindication for short-term use according to “vital” indications.For intraarticular administration: previous arthroplasty, pathological bleeding (endogenous or caused by anticoagulants), lobe fracture, infectious (septic) inflammatory process in the joint and periarticular infections (incl. in the history), as well as a general infectious disease, pronounced periarticular osteoporosis, absence of signs of inflammation in the joint (so-called “dry” joint, e.g. in osteoarthritis without synovitis), pronounced bone destruction and deformation of the joint (acute narrowing of the joint slot, ankylosis), joint instability as an outcome of arthritis, aseptic necrosis of the bones that form the joint. Parasitic and infectious diseases of viral, fungal or bacterial nature (currently or recently transmitted, including recent contact with a patient): herpes simplex, herpes zoster (viremic phase), varicella, measles; amebiasis, strongyloidosis (established or suspected); systemic mycosis; active and latent tuberculosis. Application in case of severe infectious diseases is allowed only against the background of specific therapy.
Post-vaccinal period (8 weeks before and 2 weeks after vaccination), lymphadenitis after BCG vaccination. Immunodeficiency conditions (including AIDS or HIV infection).
Gastrointestinal diseases: gastric and 12 duodenal ulcer, esophagitis, gastritis, acute or latent peptic ulcer, newly created intestinal anastomosis, nonspecific ulcerative colitis with the threat of perforation or absceration, diverticulitis.
Diseases of CCC, including recently suffered myocardial infarction (in patients with acute and subacute myocardial infarction may spread the focus of necrosis, slowing down the formation of scar tissue and as a result – rupture of heart muscle), decompensated CNS, arterial hypertension, hyperlipidemia.
Endocrine diseases: diabetes mellitus (including violation of tolerance for carbohydrates), thyrotoxicosis, hypothyroidism, Itsenko-Kushinga disease.
Severe chronic renal and/or liver failure, nephurourolithiasis.
Hypoalbuminemia and conditions predisposing to its occurrence.
Prolix Dosage Systemic osteoporosis, myasthenia gravis, acute psychosis, obesity (III-IV centuries), polio (except for the form of bulbar encephalitis), open- and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2037269/ closed-angle glaucoma, pregnancy, lactation period.
For intraarticular administration: patient’s general severe condition, ineffectiveness (or short duration) of the 2 previous administration (taking into account individual properties of the administered GCS).